MedTrace Logo

Effect of Intracameral Steroids During Phacoemulsification on the Cornea

NCT05271058 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2022-03-08

No results posted yet for this study

Summary

Prospective, interventional case control study. Sixty-nine eyes were randomized into 3 groups, 23 eyes each : 2groups received intracameral dexamethasone and triamcinolone (TA) respectively, while controls didn't receive any intraoperative steroids.

Intracameral steroids at the conclusion of phacoemulsification significantly improved corneal edema and spared corneal endothelium.

Conditions

  • Corneal Edema

Interventions

OTHER

Control group

23 eyes that didn't receive any intraoperative steroids

DRUG

Dexamethasone group

23 eyes each received intracameral dexamethasone at the conclusion of phacoemulsification Received intracameral 0.4 mg in / 0.1 ml dexamethasone (8mg/2ml®; Amriya or Epico) at the end of phacoemulsification.

DRUG

Triamcinolone (TA) group

23 eyes each received intracameral triamcinolone (TA) at the conclusion of phacoemulsification Received intracameral 2 mg/0.05 ml triamcinolone (TA) (Kenacort-A®; Bristol-Myers Squibb) at the end of phacoemulsification.

Sponsors & Collaborators

  • Beni-Suef University

    collaborator OTHER

  • Cairo University

    lead OTHER

Principal Investigators

  • Khaled G Abueleinen, MD, PhD · Ophthalmology department, Faculty of Medicine Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-16
Primary Completion
2020-06-16
Completion
2020-08-15

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05271058 on ClinicalTrials.gov